Belfast-based Neurovalens has raised £6 million in a funding round led by the Investment Fund for Northern Ireland, bringing total backing to around £20 million. The company develops non-invasive neuro-technology devices tackling major global health challenges such as insomnia, anxiety, and PTSD.

With US FDA clearance already secured, Neurovalens’ Modius Sleep and Modius Calm devices are now available in the US market and being prescribed by clinicians—marking a significant step in commercialising neuroscience-led treatments.

Read the full article here.